This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Gonadorelin injection 100mcg/vial


Powder for solution for injection containing gonadorelin 100micrograms/vial.

Drugs List

  • gonadorelin 100microgram powder for solution for injection vial
  • Therapeutic Indications


    Evaluating gonadotropic pituitary function following surgery/irradiation
    Hypopituitarism (anterior pituitary function assessment)

    Gonadorelin as a single injection is indicated for evaluating the functional capacity and response of the gonadotropes of the anterior pituitary. The LH/FSH-RH response is used in testing patients with suspected gonadotropin deficiency, whether due to the hypothalamus alone or in combination with anterior pituitary failure.

    Gonadorelin is also indicated for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumour or surgery and/or irradiation.



    100 micrograms injected subcutaneously or intravenously.
    In females for whom the phase of the menstrual cycle can be established, the test should be performed in early follicular phase (days 1 to 7).


    Children aged 1 to 18 years
    2.5 micrograms/kg (up to 100 micrograms) as a single dose, injected subcutaneously or intravenously.

    Additional Dosage Information

    Refer to product information regarding specific methodology and interpretation of test results to determine the status of the gonadotropin secretory capacity of the anterior pituitary gland.


    For subcutaneous and intravenous administration.


    Children under 1 year

    Precautions and Warnings

    Pituitary adenoma

    Contains lactose
    Exclude pregnancy prior to initiation of treatment
    Female: Ensure adequate contraception during treatment

    Ensure adequate contraception during treatment if administered during follicular phase of normal cycle, due to possible premature ovulation.

    Rare instances of hypersensitivity reactions have been reported. Therefore, if intravenous re-administration is considered in patients treated by intermittent pulsatile therapy, they should be carefully observed.

    The Norwegian Porphyria Centre (NAPOS) and the Porphyria centre Sweden, classifies gonadorelin as possibly porphyrinogenic. It should be used only when no safer alternative is available and precautions should be considered in vulnerable patients.

    Not recommended for use in patients with pituitary adenoma as haemorrhagic infarction (pituitary apoplexy) may occur.

    Pregnancy and Lactation


    Gonadorelin is contraindicated during pregnancy.

    At the time of writing, there is limited published information regarding the use of gonadorelin during pregnancy.


    Gonadorelin is contraindicated during breastfeeding.

    At the time of writing, there is limited published information regarding the use of gonadorelin during breastfeeding.

    Side Effects

    Abdominal discomfort
    Antibody formation
    Hypersensitivity reactions
    Localised and generalised rash
    Menstrual bleeding increased
    Redness of face, eyelids & lips
    Thrombophlebitis (injection site)


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: December 2018

    Reference Sources

    Summary of Product Characteristics: Gonadorelin 100 micrograms powder and solvent for solution for injection. Intrapharm Laboratories Ltd. May 2016.

    NAPOS. The drug database for acute porphyria.
    Available at:
    Pituitary and hypothalamic hormones and analogues. Last revised: September 2018.
    Last accessed: 12 December 2018.

    NICE Evidence Services Available at: Last accessed: 12 December 2018.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.